These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 12392741)

  • 1. Discovery of a potent and selective COX-2 inhibitor in the alkoxy lactone series with optimized metabolic profile.
    Leblanc Y; Roy P; Wang Z; Li CS; Chauret N; Nicoll-Griffith DA; Silva JM; Aubin Y; Yergey JA; Chan CC; Riendeau D; Brideau C; Gordon R; Xu L; Webb J; Visco DM; Prasit P
    Bioorg Med Chem Lett; 2002 Nov; 12(22):3317-20. PubMed ID: 12392741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sulfonamido, azidosulfonyl and N-acetylsulfonamido analogues of rofecoxib: 4-[4-(N-acetylsulfonamido)phenyl]-3-(4-methanesulfonylphenyl)-2(5H)furanone is a potent and selective cyclooxygenase-2 inhibitor.
    Zarghi A; Praveen Rao PN; Knaus EE
    Bioorg Med Chem Lett; 2004 Apr; 14(8):1957-60. PubMed ID: 15050636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SAR in the alkoxy lactone series: the discovery of DFP, a potent and orally active COX-2 inhibitor.
    Leblanc Y; Roy P; Boyce S; Brideau C; Chan CC; Charleson S; Gordon R; Grimm E; Guay J; Léger S; Li CS; Riendeau D; Visco D; Wang Z; Webb J; Xu LJ; Prasit P
    Bioorg Med Chem Lett; 1999 Aug; 9(15):2207-12. PubMed ID: 10465547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor.
    Prasit P; Wang Z; Brideau C; Chan CC; Charleson S; Cromlish W; Ethier D; Evans JF; Ford-Hutchinson AW; Gauthier JY; Gordon R; Guay J; Gresser M; Kargman S; Kennedy B; Leblanc Y; Léger S; Mancini J; O'Neill GP; Ouellet M; Percival MD; Perrier H; Riendeau D; Rodger I; Zamboni R
    Bioorg Med Chem Lett; 1999 Jul; 9(13):1773-8. PubMed ID: 10406640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and biological evaluation of a novel class of rofecoxib analogues as dual inhibitors of cyclooxygenases (COXs) and lipoxygenases (LOXs).
    Chen QH; Rao PN; Knaus EE
    Bioorg Med Chem; 2006 Dec; 14(23):7898-909. PubMed ID: 16904331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis, characterization, and activity of metabolites derived from the cyclooxygenase-2 inhibitor rofecoxib (MK-0966, Vioxx).
    Nicoll-Griffith DA; Yergey JA; Trimble LA; Silva JM; Li C; Chauret N; Gauthier JY; Grimm E; Léger S; Roy P; Thérien M; Wang Z; Prasit P; Zamboni R; Young RN; Brideau C; Chan CC; Mancini J; Riendeau D
    Bioorg Med Chem Lett; 2000 Dec; 10(23):2683-6. PubMed ID: 11128651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of novel cyclooxygenase-2 selective inhibitors using pharmacophore models.
    Palomer A; Cabré F; Pascual J; Campos J; Trujillo MA; Entrena A; Gallo MA; García L; Mauleón D; Espinosa A
    J Med Chem; 2002 Mar; 45(7):1402-11. PubMed ID: 11906281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and biological evaluation of 6-substituted-3-(4-methanesulfonylphenyl)-4-phenylpyran-2-ones: a novel class of diarylheterocyclic selective cyclooxygenase-2 inhibitors.
    Praveen Rao PN; Amini M; Li H; Habeeb AG; Knaus EE
    J Med Chem; 2003 Nov; 46(23):4872-82. PubMed ID: 14584938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3-(2-Methoxytetrahydrofuran-2-yl)pyrazoles: a novel class of potent, selective cyclooxygenase-2 (COX-2) inhibitors.
    Ranatunge RR; Earl RA; Garvey DS; Janero DR; Letts LG; Martino AM; Murty MG; Richardson SK; Schwalb DJ; Young DV; Zemtseva IS
    Bioorg Med Chem Lett; 2004 Dec; 14(24):6049-52. PubMed ID: 15546727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.
    Riendeau D; Percival MD; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Falgueyret JP; Ford-Hutchinson AW; Gordon R; Greig G; Gresser M; Guay J; Kargman S; Léger S; Mancini JA; O'Neill G; Ouellet M; Rodger IW; Thérien M; Wang Z; Webb JK; Wong E; Chan CC
    Br J Pharmacol; 1997 May; 121(1):105-17. PubMed ID: 9146894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.
    Chan CC; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Ford-Hutchinson AW; Forrest MJ; Gauthier JY; Gordon R; Gresser M; Guay J; Kargman S; Kennedy B; Leblanc Y; Leger S; Mancini J; O'Neill GP; Ouellet M; Patrick D; Percival MD; Perrier H; Prasit P; Rodger I
    J Pharmacol Exp Ther; 1999 Aug; 290(2):551-60. PubMed ID: 10411562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 4-Aryl/cycloalkyl-5-phenyloxazole derivatives as selective COX-2 inhibitors.
    Hashimoto H; Maeda K; Ozawa K; Haruta J; Wakitani K
    Bioorg Med Chem Lett; 2002 Jan; 12(1):65-8. PubMed ID: 11738574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thiazole analogues of the NSAID indomethacin as selective COX-2 inhibitors.
    Woods KW; McCroskey RW; Michaelides MR; Wada CK; Hulkower KI; Bell RL
    Bioorg Med Chem Lett; 2001 May; 11(10):1325-8. PubMed ID: 11392547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thalidomide and its analogues as cyclooxygenase inhibitors.
    Noguchi T; Shimazawa R; Nagasawa K; Hashimoto Y
    Bioorg Med Chem Lett; 2002 Apr; 12(7):1043-6. PubMed ID: 11909713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pyridazinones as selective cyclooxygenase-2 inhibitors.
    Li CS; Brideau C; Chan CC; Savoie C; Claveau D; Charleson S; Gordon R; Greig G; Gauthier JY; Lau CK; Riendeau D; Thérien M; Wong E; Prasit P
    Bioorg Med Chem Lett; 2003 Feb; 13(4):597-600. PubMed ID: 12639538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and biological evaluation of benzimidazole/benzothiazole and benzoxazole derivatives as cyclooxygenase inhibitors.
    Paramashivappa R; Phani Kumar P; Subba Rao PV; Srinivasa Rao A
    Bioorg Med Chem Lett; 2003 Feb; 13(4):657-60. PubMed ID: 12639552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Involvement of cyclooxygenase-derived prostaglandin E2 and nitric oxide in the protection of rat pancreas afforded by low dose of lipopolysaccharide.
    Jaworek J; Bonior J; Tomaszewska R; Jachimczak B; Kot M; Bielański W; Pawlik WW; Sendur R; Stachura J; Konturek PC; Konturek SJ
    J Physiol Pharmacol; 2001 Mar; 52(1):107-26. PubMed ID: 11321505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of rat hepatocyte culture to predict in vivo metabolic auto-induction: studies with DFP, a cyclooxygenase-2 inhibitor.
    Nicoll-Griffith DA; Silva JM; Chauret N; Day S; Leblanc Y; Roy P; Yergey JA; Dixit R; Patrick D
    Drug Metab Dispos; 2001 Feb; 29(2):159-65. PubMed ID: 11159806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new structural variation on the methanesulfonylphenyl class of selective cyclooxygenase-2 inhibitors.
    Li CS; Black WC; Brideau C; Chan CC; Charleson S; Cromlish WA; Claveau D; Gauthier JY; Gordon R; Greig G; Grimm E; Guay J; Lau CK; Riendeau D; Thérien M; Visco DM; Wong E; Xu L; Prasit P
    Bioorg Med Chem Lett; 1999 Nov; 9(22):3181-6. PubMed ID: 10576684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2,2-Dimethyl-4,5-diaryl-3(2H)furanone derivatives as selective cyclo-oxygenase-2 inhibitors.
    Shin SS; Noh MS; Byun YJ; Choi JK; Kim JY; Lim KM; Ha JY; Kim JK; Lee CH; Chung S
    Bioorg Med Chem Lett; 2001 Jan; 11(2):165-8. PubMed ID: 11206450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.